McKesson (MCK)
(Delayed Data from NYSE)
$556.15 USD
-0.55 (-0.10%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $556.37 +0.22 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$556.15 USD
-0.55 (-0.10%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $556.37 +0.22 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors are optimistic about Chemed's (CHE) Roto-Rooter business, which is witnessing continued demand for plumbing, drain cleaning services and water restoration services.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.
SmileDirectClub (SDC) Hurt by Lower Spending, Margin Woe
by Zacks Equity Research
The ongoing macroeconomic challenges continue to impact SmileDirectClub's (SDC) core demographic and business spending.
Intuitive Surgical (ISRG) Up After da Vinci SP's Japan Approval
by Zacks Equity Research
Intuitive Surgical (ISRG) gains approval in Japan for its single-port robotic surgical system, da Vinci SP. It will enable surgeons to provide minimally invasive experience for complex procedures.
Zacks Investment Ideas feature highlights: Molina Healthcare, McKesson and Humana
by Zacks Equity Research
Molina Healthcare, McKesson and Humana are part of the Zacks Investment Ideas article.
3 Top-Ranked Healthcare Stocks Thriving in 2022
by Derek Lewis
Healthcare stocks generally carry a defensive nature, helping to shield investors from the market's volatility. Demand for the services these companies provide won't be going anywhere anytime soon.
Haemonetics (HAE) Hospital Arm Aids, Macro Issues Persist
by Zacks Equity Research
Robust performance of Haemonetics' (HAE) Hospital business, on continued strength in the Hemostasis Management product line, instills optimism.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
Veeva Systems' (VEEV) Latest Launches to Enhance Workflow
by Zacks Equity Research
Veeva Systems' (VEEV) new offerings are expected to aid the marketing and field teams with more accurate and actionable insights into patient and HCP touchpoints.
McKesson (MCK) Stock Moves -1.99%: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed the most recent trading day at $342, moving -1.99% from the previous trading session.
Merit Medical (MMSI) Launches New Soft Tissue Biopsy System
by Zacks Equity Research
Merit Medical's (MMSI) launch of the TEMNO Elite Soft Tissue Biopsy System will boost its portfolio of biopsy devices.
Zacks.com featured highlights include Hyatt Hotels, McKesson and Carlsberg
by Zacks Equity Research
Hyatt Hotels, McKesson and Carlsberg are part of Zacks Screen of the Week article.
PacBio's (PACB) New Method for TR Profiling Now Available
by Zacks Equity Research
PacBio's (PACB) latest tool is expected to enable scientists to better understand the role of known TRs in human disease, which could also lead to the discovery of novel disease-causing TRs.
3 Reasons to Hold Accuray (ARAY) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.
Chemed (CHE) Roto-Rooter Business Grows, VITAS Admission Dips
by Zacks Equity Research
The performance of Chemed's (CHE) VITAS business is somewhat offset by a geographically weighted average Medicare reimbursement rate increase.
Here's Why Investors Should Hold Exact Sciences (EXAS) Stock
by Zacks Equity Research
Growth in Exact Sciences' (EXAS) legacy Screening business is attributable to Cologuard volume growth and contributions from the PreventionGenetics, Biomatrica and Oncoguard Liver products.
Stryker (SYK) Launches Q Guidance System for Spine Applications
by Zacks Equity Research
Stryker's (SYK) Q Guidance System is expected to be a procedural ecosystem for surgeons during guided spine surgery following its launch.
3 Reasons to Retain CONMED (CNMD) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
3 Stocks With Upgraded Broker Ratings for Impressive Returns
by Swayta Shah
As brokers have a deeper understanding of stocks, one must follow rating upgrades before investing. We select Hyatt Hotels (H), McKesson (MCK) and Carlsberg (CABGY) as these have seen rating upgrades recently.
PerkinElmer's (PKI) New Benchtop Platform to Boost Workflows
by Zacks Equity Research
PerkinElmer's (PKI) latest launch is expected to enable researchers to multiplex and perform immunophenotyping and viability assays in a lesser time with a simplified user interface.
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Boston Scientific (BSX) Benefits From New Buyouts, FX Woes Stay
by Zacks Equity Research
Boston Scientific's (BSX) organic growth performance is strong across all regions where most of its businesses are growing at the same pace or faster than their competitors in the respective markets.
Here's Why You Should Retain Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain momentum from robust medical sales and a solid foothold in the broader MedTech space. However, intense competition persists.